Green Cash Money

Juniper Group Inc., through its subsidiaries, provides broadband installation and wireless infrastructure construction services for wireless voice, messaging, and data service providers in the United States. The company operates in two segments, Broadband Installation and Wireless Infrastructure Services, and Film Distribution Services. The Broadband Installation and Wireless Infrastructure Services segment provides wireless, tower, and antenna system services to telecommunications companies in the United States. This segment also offers site surveys, tower construction, and tower antenna installation services to tower management companies. The Film Distribution Services segment engages in the acquisition and distribution of rights to various media, such as DVD, satellite, pay television, and broadcast television in the United States and internationally. The company was founded in 1987 and is headquartered in Boca Raton, Florida.

JNIP at 10:16 AM 7/17/2009:  New 5 minute high.

Left Behind Games, Inc. engages in the development, publishing, and distribution of video games and related products in the United States. The company develops its video game products based on the Left Behind series of novels and products. Its primary product includes LEFT BEHIND: Eternal Forces, a real time strategy game played by one person or online by up to eight players on personal computers. The company sells its products through a direct-to-store distribution channel or through distributors to Christian booksellers association and inspirational marketplaces. It markets its products in North America, Australia, Canada, Singapore, and South Africa. Left Behind Games, Inc. was founded in 2002 and is based in Murrieta, California.

LFBG at 9:44 AM 7/8/2009:  New High

BioElectronics Corporation, a development stage company, develops and markets drug-free anti-inflammatory patches. The company’s products include ActiPatch Therapy, a dermal drug-free, painless, and pulsed energy patch with an embedded battery operated microchip that delivers pulsed electromagnetic frequency therapies to accelerate healing of soft tissue injuries. Its technology provides pulsed electromagnetic energy therapy that is used to reduce swelling, relieve pain, and enhance the healing of post-surgical incisions, chronic wounds, and orthopedic conditions. The company has market clearance/approval for its products in the United States, Canada, and Europe. BioElectronics Corporation sells its products to wholesale distributors, and directly to hospitals and clinics. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.

BIEL at 10:05 AM 6/29/2009: Trading 6% above VWAP

SpongeTech Delivery Systems, Inc. designs, produces, and markets unique lines of reusable cleaning products for car care, child care, home care, and pet care usages. These sponge-like products utilize SpongeTech’s proprietary, patent (and patent-pending) technologies, and other technologies involving hydrophilic (liquid absorbing) foam, polyurethane matrices, or other ingredients. The company’s sponge-like products are pre-loaded with specially formulated ingredients, such as soap, conditioner, and/or wax that are released when the sponge is soaked and applied to a surface with minimal pressure. SpongeTech Delivery Systems is exploring additional applications for its technology in the health, beauty, and medical markets. It plans to globally brand its company as America’s Cleaning Company. The company was founded in 1999 and is based in New York, New York.

SPNG at 11:15 AM 6/5/2009: Fibonacci buy signal.

Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH. The company was founded in 1980 and is based in Boonton, New Jersey.

UGNE at 10:19 AM 6/1/2009:  Crossed daily highs resistance

mPhase Technologies, Inc., a development company, specializes in microfluidics, microelectromechanical systems, and nanotechnology. The company, through its subsidiary, AlwaysReady, Inc., focuses on commercializing Smart NanoBattery, which provides power “on command” for military and commercial applications. Its patented battery technology, based on the phenomenon of electrowetting, stores energy and manages power. The technology of Smart NanoBattery is a porous nanostructured material that could be designed for self-cleaning applications, water purification/desalination, liquid filtration/separation, and environmental cleanup. The company was founded in 1996 and is headquartered in Little Falls, New Jersey with additional offices in Norwalk, Connecticut; and New York, New York.

XDSL at 9:44 AM 5/28/2009:  Price crossed above VWAP (0.0299).  Confirmed by volume.

Genta Incorporated operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The company’s lead compound from its DNA/RNA Medicines program is Genasense (oblimersen sodium) injection that is designed to block the production of a protein, known as Bcl-2, which is a fundamental cause of the inherent resistance of cancer cells to anticancer treatments, such as chemotherapy, radiation, and monoclonal antibodies. Genta Incorporated is recruiting patients to the AGENDA Trial, a global Phase III trial of Genasense in patients with advanced melanoma. Its lead drug in its Small Molecule program is Ganite (gallium nitrate injection), which is marketed in the United States for the treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The company also develops G4544, an oral formulation of the active ingredient in Ganite, which entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. In addition, it is developing tesetaxel, an orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. The company was founded in 1988 and is based in Berkeley Heights, New Jersey.

GNTA at 10:01 AM 5/26/2009:  Running up quickly